RESUMENAntecedentes: El cáncer cérvico uterino es la quinta causa de muerte por cáncer en la mujer chilena. Objetivo: Comparar entre agosto de 1999 y diciembre de 2002 la sobrevida por cáncer cérvico uterino según estadio clínico a 3 y 5 años diagnosticados en la Unidad de Patología Cervical del Hospital San José. Méto-do: La sobrevida se calculó con la totalidad de casos de cáncer cérvico uterinos diagnosticados, su estadio y mortalidad a 3 y 5 años obtenidos a través del Registro Civil de Chile. Resultados: La distribución por estadio fue: 22,2% para estadio I, 21,3% para estadio II, 53,7% para estadio III y 2,7% para estadio IV. En estadio I la sobrevida a 3 años fue de 83% (IC: 61,5 -93,4) y a 5 años de 78% (IC: 55,5 -90,5); en estadio II fue de 65% (IC: 42,4 -80,8) y de 60% (IC: 38,3 -77,4), respectivamente; en estadio III fue de 33% (IC: 21,6 -45,5) y 29% (IC: 18,6 -41,9), respectivamente; y en estadio IV la mortalidad a 3 y 5 años fue de 100% produciéndose el deceso durante los tres primeros meses desde su diagnóstico. Conclusión: La sobrevida se correlaciona directamente con el estadio clínico en el momento del diagnóstico, independiente de la edad de la paciente, debiendo aumentar la cobertura del tamizaje, mejorando los tiempos de confirmación diagnóstica y tratamiento óptimo, como también mejorando los sistemas de redes y registros. The overall survival rate was calculated with the totality of diagnosed cervical cancer, his stage and mortality in 3 and 5 years was obtained through the National Registry Office. Results: The distribution for stage was: 22.2% for stage I, 21.3% for stage II, 53.7% for stage III and 2.7% for stage IV. In stage I the survival at 3 years was 83% (CI: 61.5 -93.4), and at 5 years 78% (CI: 55.5 -90.5). In stage II the survival at 3 years was 65% (CI: 42.4 -80.8) and at 5 years 60% . In stage III the survival at 3 years was 33% (CI: 21.6 -45.5) and at 5 years 29% (CI: 18.6 -41.9). In stage IV the mortality at 3 and 5 years was 100% produced during the first 3 months from the diagnosis. Conclusions: The survival is directly correlative with the clinical stage in the moment of the diagnosis, independent of the age of the patients, by which it must increase the screening coverage, improving the times of diagnostic confirmation and optimum treatment, and also improving the network systems and registries.
0.61). Self-evaluation of PDA decreased as the age of children increased, with OR of 0.76 (95% IC 0.74 -0.79); 0.87 (95% IC 0.83 - 0.91) and 0.92 (95% IC 0.88 - 0.96) for PH, MD and MG respectively. An inverse relationship between nutritional status (NS) and PDA was observed only in PH, obese school children underscored their PH (OR 0.6; 95% IC 0.5 - 0.7). Multivariate analysis for gender and NS showed that only females overestimate their PH, OR of 1.15 (95% IC 1-1.32). Conclusions: PDA through self-assessment yields only moderate correlation coefficients, thus it is not reliable for making relevant clinical decisions.]]>
Dialysis dose, nutrition and growth among pediatric patients on peritoneal dialysis Background: Stunting is common among pediatric patients on peritoneal dialysis. Aim: To stablish the best profile for urea kinetic variables associated to growth in children on chronic peritoneal dialysis (PD). Patients and Methods: Twenty patients, aged 1 month to 14 years, 13 males, were followed for 6-12 months, with monthly measurements of weight/age and height/age Z score; plasma creatinine, BUN, protein and albumin and urine and dialysate urea nitrogen, creatinine, protein and albumin. Minimum total Kt/V was 2.1. Dialysis dose (Kt/V), Protein Equivalent of Urea Nitrogen Appearence (PNA), Protein Catabolic Rate (PCR) and Nitrogen Balance (NB) were calculated. To identify the variable(s) associated to growth, the Tree Classification Model (CART) Enterprise Miner 8.1 was applied. Results: Mean total/residual Kt/V: 3.4±1.3/1.69±1.27; Daily Protein Intake (DPI) was 3.25±1.27 g/kg/day. nPNA, PCR and NB were 1.37±0.44, 0.84±0.33 and 1.86±1.25 g/kg/day, respectively. Mean heigth/age Z score was-2.3±1.19. Eleven patients showed a positive height/age delta Z (mean 0.55±0.38) and nine showed a negative growth (mean-0.50±0.42). The main variable explaining the positive growth was a Nitrogen Balance between 0.54 and 2.37 g/kg/ day, mean 1.55±0.21 (p <0.001). The second associated variable to growth was a residual Kt/V between 0.43 and 4.6 (2.02±0.49) (p <0.05). Kt/V and nPNA showed a significant correlation, but no correlation could be found between Kt/V and NB. Conclusions: Nitrogen Balance was the main variable associated to growth in pediatric PD, with values between 0.53 to 2.38 g/kg/day. The second variable was a residual Kt/V between 0.43 and 4.6. Therapy should be reassessed with NB values less than 0.54 or above 2.37 g/kg/day
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.